End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
1.98 EUR | -1.00% | -1.00% | -1.00% |
May. 29 | Neovacs: mRNA approach validated in preclinical trial | CF |
May. 27 | Neovacs: collaboration contract with INSERM team | CF |
Sales 2022 | 1.11K 1.21K | Sales 2023 | 533K 579K | Capitalization | 278 301.71 |
---|---|---|---|---|---|
Net income 2022 | -3M -3.26M | Net income 2023 | -8M -8.68M | EV / Sales 2022 | - |
Net cash position 2022 | 5.55M 6.03M | Net cash position 2023 | 237K 257K | EV / Sales 2023 | -0.44 x |
P/E ratio 2022 * |
-
| P/E ratio 2023 |
-0.08
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 0.12% |
1 day | -1.00% |
Managers | Title | Age | Since |
---|---|---|---|
Hugo Brugière
CEO | Chief Executive Officer | - | - |
Director of Finance/CFO | - | 20-09-30 | |
Vincent Serra
COO | Chief Operating Officer | 55 | 19-02-19 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 85 | 03-05-27 | |
Daniel Zagury
FOU | Founder | - | 93-04-15 |
Hugo Brugière
CEO | Chief Executive Officer | - | - |
1st Jan change | Capi. | |
---|---|---|
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B | |
-11.83% | 10.74B |
- Stock Market
- Equities
- ALNEV Stock
- ALNEV Stock